prednisone/prednisolone

ApprovedSmall molecule

prednisone/prednisolone is one of 306 small molecule programs targeting Pemphigus Vulgaris. It is currently in Approved.

Indications

Total Trials

Active Trials

305

Competitors

Pipeline

Status by Indication[3][1]

Indication

Pemphigus VulgarisActive, not recruiting

Anterior UveitisActive, not recruiting

LymphomaActive, not recruiting

Prostate CancerActive, not recruiting

Diffuse Large B-Cell LymphomaActive, not recruiting

Myasthenia GravisActive, not recruiting

AsthmaActive, not recruiting

Metastatic Castration-Resistant Prostate CancerRecruiting

Solid TumorActive, not recruiting

Advanced Solid TumorActive, not recruiting

Pemphigus VulgarisPhase 3

Active, not recruiting

Anterior UveitisPhase 2

Active, not recruiting

LymphomaPhase 3

Active, not recruiting

Prostate CancerPreclinical

Active, not recruiting

Diffuse Large B-Cell LymphomaPhase 3

Active, not recruiting

Myasthenia GravisApproved

Active, not recruiting

AsthmaApproved

Active, not recruiting

Metastatic Castration-Resistant Prostate CancerPhase 3

Recruiting

Solid TumorPhase 1

Active, not recruiting

Advanced Solid TumorPhase 1

Active, not recruiting

Showing 10 of 13 indications

Competition

Competitive Landscape

1774 competitors in Lymphoma

#DrugCompanyPhaseTrials

prednisone/prednisolone

Roche

Approved

3 2

Blenoxane

SSequus Pharmaceuticals

Preclinical

25 3

Velban

EEastern Cooperative Oncology Group

Preclinical

15 4

Zofran

Novartis

Preclinical

2 5

Norvir

AbbVie

Preclinical

1 6

Wellcovorin

GGlaxo Dba Glaxosmithkline

Preclinical

4 7

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 8

Kenalog

BBausch Health Americas, Inc.

Preclinical

1 9

Decadron

QQuince Therapeutics S.p.A.

Preclinical

—10

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Active, not recruiting

Lymphoma

NCT03407144

Q1 2027

Phase 1Active, not recruiting

Solid Tumor

NCT06421935

Q3 2027

Post-ApprovalNot yet recruiting

Myasthenia Gravis

NCT07221838

Q3 2029

Phase 3Recruiting

Diffuse Large B-Cell Lymphoma(dlbcl)

NCT06091865

Clinical

Trials by Indication[1]

Lymphoma3 trials

Study Comparing Inotuzumab Ozogamicin In Combination With Rituximab Versus Defined Investigator's Choice In Follicular Non-Hodgkin's Lymphoma (NHL)

Terminated· Pfizer logo

Pfizer·Phase 3·NCT00562965·29 enrolled

Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667)

Active, not recruiting· Merck & Co. logo

Merck & Co.·Phase 2·NCT03407144·340 enrolled

A Study of Rituximab (MabThera) Subcutaneous (SC) Versus Rituximab (MabThera) Intravenous in Participannts With Follicular Non-Hodgkin's Lymphoma

Completed· Roche logo

Roche·Phase 3·NCT01200758·410 enrolled

Prostate Cancer3 trials

Abiraterone Acetate in Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy

Completed·CCougar Biotechnology, Inc.·Phase 3·NCT00638690·1,195 enrolled

Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer

Completed· Roche logo

Roche·Phase 3·NCT03072238·1,101 enrolled

Study of Abiraterone Acetate in Patients With Advanced Prostate Cancer

Approved for marketing· Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logo

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.··NCT01217697

Asthma2 trials

A Serious Asthma Outcome Study With Mometasone Furoate/Formoterol Versus Mometasone Furoate in Asthmatics 12 Years and Over (P06241)

Completed·OOrganon and Co·Phase 4·NCT01471340·11,744 enrolled

Study of Efficacy and Long-Term Safety of Mometasone Furoate in Combination With Formoterol Fumarate Versus Mometasone Furoate in Children (5 to 11 Years of Age) With Persistent Asthma (MK-0887A-087)

Completed·OOrganon and Co·Phase 3·NCT02741271·181 enrolled

Follicular Lymphoma1 trial

A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)

Recruiting· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT06911502·400 enrolled

Abiraterone Acetate1 trial

Pre-approval Access Single Patient Request for Niraparib / Abiraterone Acetate Combination (Nira/AA Combination)

Approved for marketing· Johnson & Johnson logo

Johnson & Johnson··NCT05401214

9 more indications

Myasthenia Gravis1 trial

A Study to Investigate OCS Tapering in Adult Participants With Generalized Myasthenia Gravis Treated With Ravulizumab

Not yet recruiting· AstraZeneca logo

AstraZeneca·Phase 4·NCT07221838·75 enrolled

Anterior Uveitis1 trial

A Trial of the Efficacy and Safety of Izokibep in the Treatment of Non-anterior Uveitis

Completed·AACELYRIN Inc.·Phase 2·NCT04706741·7 enrolled

B-cell Malignancies1 trial

Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT04599634·11 enrolled

Pemphigus Vulgaris1 trial

Long-Term Extension Study of Ofatumumab in Subjects With Pemphigus Vulgaris

Terminated· GSK logo

GSK·Phase 3·NCT02613910·1 enrolled

Cancer of the Prostate1 trial

Radium-223 Dichloride and Abiraterone Acetate Compared to Placebo and Abiraterone Acetate for Men With Cancer of the Prostate When Medical or Surgical Castration Does Not Work and When the Cancer Has Spread to the Bone, Has Not Been Treated With Chemotherapy and is Causing no or Only Mild Symptoms

Completed· Bayer logo

Bayer·Phase 3·NCT02043678·806 enrolled

Diffuse Large B-cell Lymphoma(DLBCL)1 trial

A Phase 3, Open Label, Randomized Study Comparing the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20 × Anti-CD3 Bispecific Antibody, in Combination With CHOP (ODRO-CHOP) Versus Rituximab in Combination With CHOP (R-CHOP) in Previously Untreated Participants With Diffuse Large B-cell Lymphoma (DLBCL) (OLYMPIA-3)

Recruiting· Regeneron logo

Regeneron·Phase 3·NCT06091865·904 enrolled

Solid Tumor1 trial

An Open Label, Multicenter, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Profile of the PARP1 Inhibitor M9466 Alone or in Combination in Participants With Advanced Solid Tumors

Active, not recruiting· EMD Serono Research & Development Institute, Inc. logo

EMD Serono Research & Development Institute, Inc.·Phase 1·NCT06421935·60 enrolled

Metastatic Castration-Resistant Prostate Cancer1 trial

A Phase III, Randomized, Open-label Trial of BNT324 Versus Docetaxel With Prednisone/Prednisolone in Metastatic Castration-resistant Prostate Cancer

Recruiting· BioNTech logo

BioNTech·Phase 3·NCT07365995·736 enrolled

Follicular Lymphoma (FL)1 trial

A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20 X Anti-CD3 Bispecific Antibody Versus Investigator's Choice in Previously Untreated Participants With Follicular Lymphoma (OLYMPIA-1)

Recruiting· Regeneron logo

Regeneron·Phase 3·NCT06091254·822 enrolled

Sources

References

[1]
ClinicalTrials.gov — 19 trial records for prednisone/prednisolone. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — prednisone/prednisolone compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for prednisone/prednisolone. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Roche company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Roche

prednisone/prednisolone

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q1 2027

Q3 2027

Q3 2029

Trials by Indication[1]

Lymphoma3 trials

Prostate Cancer3 trials

Asthma2 trials

Follicular Lymphoma1 trial

Abiraterone Acetate1 trial

Myasthenia Gravis1 trial

Anterior Uveitis1 trial

B-cell Malignancies1 trial

Pemphigus Vulgaris1 trial

Cancer of the Prostate1 trial

Diffuse Large B-cell Lymphoma(DLBCL)1 trial

Solid Tumor1 trial

Metastatic Castration-Resistant Prostate Cancer1 trial

Follicular Lymphoma (FL)1 trial

References

Drug Info

Quick Facts

Related News